
 BRIGHAM AND WOMEN'S HOSPITAL 

---

## Dupuytren's Disease: Enzymatic Fasciotomy

**Philip Blazar** MD, PhD

---

---

---

---

---

---

---

---

### Disclosures

- 1) Auxilium/Endo Pharmaceuticals Research Funding, Scientific Advisory Board

---

---

---

---

---


---

---

---

### Treatment Options

- Fasciectomy: Open Surgery
- NA: The Needle
- CCH: Injection



---

---

---

---

---


---

---

---

### Comparison

- Efficacy:
  - ROM restoration
- Recurrence
  - Scar vs. Cord
  - How many degrees?
  - Treated finger/Joint vs. new disease
- Complications



---

---

---

---

---

---

---

### Fasciectomy: "Open Surgery"

- Comfortable
- Effective 80% reduction in FFC
- Complications 5-15%
  - (Digital nerve, infection, hematoma)
  - Flexion deficits
- Recurrence 5yrs 21%

• *van Rijssen JHS 2006, 2012 PRS*  
• *Smeraglia BR Med Bull 2016*



---

---

---

---

---

---

---

### Surgery: Partial Fasciectomy



---

---

---

---

---

---

---

## Slide 5


---

**LH5** what's the goal here - i can find better surgical slides

Larry Hurst, 1/7/2009

**S5** if you would like to put a better pic in great. just for visual... we will have more later too with case.

Sara, 1/8/2009



---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---



---

---

---

---

---


---

---

---

### NA: "the needle"

- Short term results are good
- Effective 63% reduction in FFC
- Complication rate is low <1%
- Less invasive
- Recurrence 5yrs 85%



van Rijssen JHS 2006, 2012 PRS: Nydick, VanRijssen, Pess, Denkler, Eaton....

---

---

---

---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---



---

---

---

---

---



---

---

---

**CCH: "injection"**

- FDA approved 2010
- Effective (80% MP, 49% PIP)
- Complication rate is low
- Recurrence (5yrs) 47%-CORDLESS
- 2 (vs. 39 days) Normal ADL activity



- Peimer JHS 2015
- Naam Hand 2013
- Smeriglia BR MED Bull 2016

---

---

---

---

---


---

---

---

### CCH

- FDA approved 2010
- Effective (80% MP, 49% PIP)
- Complication rate is low
- Recurrence (5yrs) 47%-CORDLESS
- 2 (vs. 39 days) Normal activity



- Peimer JHS 2015
- Naam Hand 2013
- Smeriglia BR MED Bull 2016

---

---

---

---

---

---

---


---

### Head to Head trials

-NA vs. CCH: No sig Difference but limited F/u of prospective  
*Nydick JHS 2013, Skov JHS 2017, Stromberg JHS 2016, Scherman JHSE 2016*

-CCH vs. Surgery: : MP no difference, PIP surgery slightly better correction but more complications  
*Zhou PRS 2015, Povlsen Hand 2014, Tay Hand 2015*

-Surgery vs. NA Recurrence lower with surgery.  
Infections higher with surgery  
*van Rijssen 2012, Toppi Anz J Surg 2015*



---

---

---

---



---

---

---

---

### Decision?



---

---

---

---

---

---

---

---

Patient's choice



---

---

---

---

---

---

---

---

Decision?



---

---

---

---

---

---

---

---

 BRIGHAM AND  
WOMEN'S HOSPITAL



 HARVARD  
MEDICAL SCHOOL  
TEACHING AFFILIATE

---

---

---

---


---

---

---

---





---

---

---

---

---

---

---

---

### Literature

Hay et. al. JHS E, 2013. 9/15 cases felt to technically similar to primary

Eberlin et al. PRS 2015. *“Collagenase clostridium histolyticum injections may produce a deeply scarred bed and increase the technical difficulty of salvage fasciectomy. However, results of palmar fasciectomy are comparable to those of primary fasciectomy even in the setting of recurrent or progressive disease.”*



---

---

---

---

---

---

---

---

## Slide 22

---

**LH4** what's the goal here - i can find better surgical slides

Larry Hurst, 1/7/2009

**S4** if you would like to put a better pic in great. just for visual... we will have more later too with case.

Sara, 1/8/2009